Development of Orally Bioavailable Peptides Targeting an Intra-cellular Protein: From a Hit to a Clinical KRAS Inhibitor
Masahiro Kojima
Researcher, Chugai Pharmaceutical Co., Ltd.
Cyclic peptides as a therapeutic modality have received notable attention due to their potential for oral absorption and accessibility to intracellular tough targets. In this presentation, the concept of our cyclic peptide drug discovery platform and as the first example from this technology, the discovery of a RAS inhibitory clinical compound (LUNA18) will be introduced.
Masahiro Kojima earned his PhD in synthetic organic chemistry at the University of Tokyo. After his study in UC Berkeley and in Hokkaido University, he joined discovery chemistry department of Chugai Pharmaceutical.